US 11,932,646 B2
Small molecule myristate inhibitors of Bcr-abl and methods of use
Nathanael S. Gray, Boston, MA (US); Jianming Zhang, Belmont, MA (US); Barun Okram, San Marcos, CA (US); Xianming Deng, Fujian (CN); Jae Won Chang, San Diego, CA (US); and Amy Wojciechowski, Cheektowaga, NY (US)
Assigned to THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA (US); and DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US); and The Scripps Research Institute, La Jolla, CA (US)
Filed on Jan. 12, 2022, as Appl. No. 17/574,132.
Application 16/933,095 is a division of application No. 16/170,921, filed on Oct. 25, 2018, granted, now 10,787,455, issued on Sep. 29, 2020.
Application 16/170,921 is a division of application No. 15/582,004, filed on Apr. 28, 2017, abandoned.
Application 17/574,132 is a continuation of application No. 16/933,095, filed on Jul. 20, 2020, granted, now 11,254,682.
Application 15/582,004 is a continuation of application No. 14/540,919, filed on Nov. 13, 2014, granted, now 9,670,214, issued on Jun. 6, 2017.
Application 14/540,919 is a continuation of application No. 12/745,496, granted, now 8,921,336, issued on Dec. 30, 2014, previously published as PCT/US2008/013219, filed on Nov. 28, 2008.
Claims priority of provisional application 61/004,462, filed on Nov. 28, 2007.
Prior Publication US 2022/0135573 A1, May 5, 2022
Int. Cl. C07D 239/94 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/52 (2006.01); A61K 31/5377 (2006.01); A61K 31/7076 (2006.01); A61K 45/06 (2006.01); A61P 9/00 (2006.01); A61P 17/00 (2006.01); A61P 19/00 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07D 239/42 (2006.01); C07D 403/04 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 417/04 (2006.01); C07D 471/04 (2006.01); C07D 473/34 (2006.01); C07D 487/04 (2006.01); C07D 495/04 (2006.01); C07H 19/16 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/52 (2013.01); A61K 31/5377 (2013.01); A61K 31/7076 (2013.01); A61K 45/06 (2013.01); A61P 9/00 (2018.01); A61P 17/00 (2018.01); A61P 19/00 (2018.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07D 239/42 (2013.01); C07D 239/94 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 417/04 (2013.01); C07D 471/04 (2013.01); C07D 473/34 (2013.01); C07D 495/04 (2013.01); C07H 19/16 (2013.01); Y02A 50/30 (2018.01)] 4 Claims
 
1. A compound of formula VII, or pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
wherein
R1 is selected from a substituted C1-6alkyl, —C(O)Rx, (CH2)nC(O)Rx, (CH2)nC(O)ORx, (CH2)nC(O)NRxRx, or —(CH2)nC(O)NRxRxS(O)2Rx;
Rx, for each occurrence, is independently H, an optionally substituted C1-6alkyl, an optionally substituted C3-12cycloalkyl, an optionally substituted C3-12heterocycloalkyl, an optionally substituted C3-12aryl, an optionally substituted C3-12heteroaryl, NHNHR2, or C(NH)NH2;
R2 is H or C1-4 alkyl; and
each n is independently 0, 1 or 2,
wherein the substituted C1-6alkyl is not ethyl.